Blackstone’s bid to acquire I’rom raises competition concerns over clinical trials
The ACCC has red flags about the acquisition of Japanese healthcare business I’rom Group by private equity behemoth Blackstone.
The ACCC has red flags about the acquisition of Japanese healthcare business I’rom Group by private equity behemoth Blackstone.
For information on rights and reprints, contact subscriptions@lawyerly.com.au